Appropriate use of antimicrobial drugs: A better prescription is needed

JAMA

Volumn 294, Issue 18, 2005, Pages 2354-2356

  Weber, J Todd ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLAVULANIC ACID; ERYTHROMYCIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BETA HEMOLYTIC STREPTOCOCCUS; EDITORIAL; GOVERNMENT; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INDUSTRIALIZATION; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PHARYNGITIS; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REDUCTION; RESPIRATORY TRACT INFECTION; VIRUS INFECTION; DRUG RESISTANCE; DRUG UTILIZATION; NOTE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE; DRUG UTILIZATION; HUMANS; PRESCRIPTIONS, DRUG; RESPIRATORY TRACT INFECTIONS;

EID: 27744595608     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.18.2354     Document Type: Editorial

References (30)

1. Howard DH, Scott RD. The economic burden of drug resistance. Clin Infect Dis. 2005;41:S283-S286.
2. Department of Health and Human Services; Centers for Disease Control and Prevention. Get Smart: Know When Antibiotics Work Web site. July 12, 2005. Available at: http://www.cdc.gov/drugresistance/community/partners.htm. Accessed October 6, 2005.
3. McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA. 2002;287:3096-3102.
4. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000 [published correction appears in Emerg Infect Dis. 2003;9:609]. Emerg Infect Dis. 2003;9:432-437.
5. Linder JA, Bates DW, Lee GM, Finkelstein JA. Antibiotic treatment of children with sore throat. JAMA. 2005;294:2315-2322.
6. Samore MH, Bateman K, Alder SC, et al. Clinical decision support and appropriateness of antimicrobial prescribing: a randomized trial. JAMA. 2005;294:2305-2314.
7. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis. 2005;11:802-807.
8. Weissman J, Besser RE. Promoting appropriate antibiotic use for pediatric patients: a social ecological framework. Semin Pediatr Infect Dis. 2004;15:41-51.
9. National Committee for Quality Assurance. The State of Healthcare Quality 2004: Industry Trends and Analysis. Available at: http://www.ncqa.org/ Communications/SOMC/SOHC2004.pdf. Accessed October 4, 2005.
10. Harbarth S, Samore MH. Antimicrobial resistance determinants and future control. Emerg Infect Dis. 2005;11:794-801.
11. Linder JA. Health information technology as a tool to improve care for acute respiratory infections. Am J Manag Care. 2004;10:661-662.
12. Tokars JI, Richards C, Andrus M, et al. The changing face of surveillance for health care-associated infections. Clin Infect Dis. 2004;39:1347-1352.
13. Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg. 2005;140:174-182.
14. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115:632-641.
15. Bloland PB, Kachur SP, Williams HA. Trends in antimalarial drug deployment in sub-Saharan Africa. J Exp Biol. 2003;206:3761-3769.
16. World Health Organization. Second Joint FAO/OIE/WHO Expert Workshop on Non-Human Antimicrobial Usage and Antimicrobial Resistance: Management Options; March 15-18, 2004; Oslo, Norway. Available at: http://www.who.int/salmsurv/ links/en/WHO_CDS_CPE_ZFK_2004.8.pdf. Accessed October 2, 2005.
17. Powers JH. Antimicrobial drug development - the past, the present, and the future. Clin Microbiol Infect. 2004;10(suppl 4):23-31.
18. Livermore DM. The need for new antibiotics. Clin Microbiol Infect. 2004;10(suppl 4):1-9.
19. Department of Health and Human Services; US Food and Drug Administration. Linezolid approval. Available at: http://www.fda.gov/cder/foi/appletter/2000/ 21130ltr.pdf. Accessed April 5, 2005.
20. Department of Health and Human Services; US Food and Drug Administration. Daptomycin approval. Available at: http://www.fda.gov/cder/foi/appletter/2003/ 21572ltr.pdf. Accessed April 5, 2005.
21. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259-268.
22. Pletz MW, McGee L, Jorgensen J, et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Clin Infect Dis. 2005;41:139-148.
23. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis. 2005;41:923-929.
24. McDonald LC. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol. 2005;26:672-675.
25. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38:640-645.
26. Bozeman L, Burman W, Metchock B, Welch L, Weiner M; Tuberculosis Trials Consortium. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis. 2005;40:386-391.
27. Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003;168:1342-1345.
28. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother. 2004;48:780-782.
29. Ghanem KG, Giles JA, Zenilman JM. Fluoroquinolone-resistant Neisseria gonorrhoeae: the inevitable epidemic. Infect Dis Clin North Am. 2005;19:351-365.
30. Department of Health and Human Services; US Food and Drug Administration. Withdrawal of Approval of the New Animal Drug Application for Enrofloxacin in Poultry. July 29, 2005. Available at: http://www.fda.gov/oc/antimicrobial/ baytril.pdf. Accessed October 3, 2005.